Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
December’s full moon is the last supermoon of the year. Here’s what to know - 2Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- 3'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- 4What to know about the "wild, wild West" of viral peptide claims
- 512 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- Irish defence minister's trip to Lebanon cancelled
- Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- Illustrations Gained from a Crosscountry Excursion
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- 12 times rockets and spacecraft crashed and burned in 2025
- Spain and Catholic Church agree to compensate sex abuse victims
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
